Table 1 Humoral and cellular vaccination response
Humoral | Cellular | |||||
|---|---|---|---|---|---|---|
No response | Response | P | No response | Response | p | |
Patients, n (%) | 21 (61.8) | 13 (38.2) | 2 (8.0) | 23 (92.0) | ||
Female, n (%) | 8 (38.1) | 7 (54.8) | 0 (0.0) | 9 (39.1) | ||
Mean Age at vaccination (SD) | 62.6 (15.7) | 53.5 (18.5) | 0.07 | 66.0 (22.6) | 55.7 (16.9) | † |
Cause for Immunosuppression | ||||||
AAV, n (%) | 18 (85.7) | 4 (30.8) | 2 (100.0) | 12 (52.2) | ||
FSGS, n (%) | 1 (4.8) | 0 (0.0) | 0 (0.0) | 1 (4.3) | ||
MGN, n (%) | 1 (4.8) | 2 (15.4) | 0 (0.0) | 2 (8.7) | ||
MC, n (%) | 1 (4.8) | 2 (15.4) | 0 (0.0) | 3 (13.0) | ||
TMA, n (%) | 0 (0.0) | 4 (30.8) | 0 (0.0) | 4 (17.4) | ||
M. Goodpasture, n (%) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 1 (4.3) | ||
Current immunosuppression | ||||||
Anti-CD20 antibody | ||||||
Regular regimen, n (%) | 17 (81.0) | 3 (23.1) | 2 (100.0) | 12 (52.2) | ||
Irregular regimen, n (%) | 4 (19.0) | 10 (76.9) | 0 (0.0) | 11 (47.8) | ||
Steroid, n (%) | 12 (57.1) | 1 (7.7) | 2 (100.0) | 6 (26.1) | ||
Hydroxychloroquine, n (%) | 0 (0.0) | 1 (7.7) | 1 (50.0) | 0 (0.0) | ||
Previous immunosuppression | ||||||
Cyclophosphamide, n (%) | 13 (61.9) | 5 (38.5) | 2 (100.0) | 9 (39.1) | ||
High-dose Steroid, n (%) | 20 (95.2) | 13 (100.0) | 2 (100.0) | 22 (95.7) | ||
Mycophenolate Mofetil, n (%) | 5 (23.8) | 3 (23.1) | 0 (0.0) | 8 (34.8) | ||
Azathioprine, n (%) | 1 (4.8) | 1 (7.7) | 0 (0.0) | 2 (8.7) | ||
Cyclosporine A, n(%) | 5 (23.8) | 3 (23.1) | 0 (0.0) | 8 (34.8) | ||
Leflunomide, n (%) | 1 (4.7) | 0 (0.0) | 0 (0.0) | 1 (4.3) | ||
Metotrexate, n (%) | 1 (4.3) | 0 (0.0) | 0 (0.0) | 1 (4.3) | ||
Kidney function | ||||||
eGFR, CKD-EPI; ml/min/1.73m2 (SD) | 47.4 (25.5) | 63.2 (26.9) | 0.11 | 53.5 (30.4) | 60.2 (24.0) | † |
Proteinuria, g/g (SD) | 1.2 (3.0) | 1.0 (1.9) | 0.30 | 0.5 (0.6) | 1.2 (3.0) | † |
Hematuria, Stix (SD) | 1.4 (1.3) | 0.7 (0.8) | 0.15 | 0.5 (0.7) | 1.1 (1.2) | † |
Vaccines used | ||||||
2 × BNT162b2, n (%) | 16 (76.2) | 9 (69.2) | 2 (100.0) | 15 (65.2) | ||
2 × mRNA-1273, n (%) | 1 (4.8) | 0 (0.0) | 0 (0.0) | 1 (4.3) | ||
2 × ChAdOx1, n (%) | 1 (4.8) | 2 (15.4) | 0 (0.0) | 3 (13.0) | ||
1 × Ad26.COV2.S, n (%) | 2 (9.5) | 1 (7.7) | 0 (0.0) | 2 (8.7) | ||
1 × ChAdOx1, 1 × BNT162b2, n (%) | 1 (4.7) | 0 (0.0) | 0 (0.0) | 1 (4.3) | ||
1 × ChAdOx1, 1 × mRNA-1273, n (%) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 1 (4.3) | ||
Vaccination characteristics | ||||||
Days anti-CD20 antibody to 1st vaccination (SD) | 111.2 (51.7) | 553.5 (553.8) | < 0.01 | 131.0 (50.9) | 327.4 (453.5) | † |
CD19 counts at vaccination, cells/µl (SD) | 1.2 (4.6) | 146.1 (241.1) | < 0.01 | 0.5 (0.7) | 74.4 (191.9) | † |
Days between 1st and 2nd vaccine (SD) | 44.8 (17.6) | 42.3 (22.2) | 0.26 | 30.0 (7.1) | 46.6 (21.0) | † |
Days full vaccination to laboratory analysis (SD) | 35.7 (29.6) | 46.6 (36.7) | 0.30 | 83.0 (49.5) | 40.0 (32.9) | † |